Namir Hassan

Namir Hassan

Company: Zelluna Immunotherapy

Job title: Chief Executive Officer

Seminars:

TCR-NK: A Novel Paradigm to Drive Durable Responses in Solid Cancers 3:15 pm

TCR based therapies have shown compelling tumour responses across various solid cancers; however, virtually all patients with advanced solid tumours showing initial response to treatment relapse Heterogeneity of target expression and / or loss of target have been clinically demonstrated to drive relapse in patients where cancers evade T cell recognition Arming NK cells with…Read more

day: Day 1 - Track A - Mid

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.